RecruitingNCT07200375

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study

Sponsor

Hoffmann-La Roche

Enrollment

300 participants

Start Date

Sep 29, 2025

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma

Summary

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Histologically confirmed R/R DLBCL after one line of systemic therapy
Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment

Exclusion Criteria1

Participants who currently participate in or plan to participate in any interventional clinical trial

Interventions

DRUGGlofitamab

Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Locations(12)

Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center

Tianjin, Tianjin Municipality, China

Peking University Third Hospital

Beijing, China

The First Bethune Hospital of Jilin University

Changchun, China

Guangdong Provincial People's Hospital

Guangzhou, China

Harbin Medical University Cancer Hospital

Harbin, China

Shandong Cancer Hospital

Jinan, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Tianjin Cancer Hospital

Tianjin, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

Wuhan, China

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, China

Henan Cancer Hospital

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07200375

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716120 locations

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT060263191 location

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347246 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location